Deal Tracker · Countries

Chile pharma deals

3 pharma deals involving Chile — companies based there or deals covering the market — tracked by EPT: licensing & M&A. Most active: Eurofarma, Laboratorio Chile, Laboratorio Libra & Laboratorios Siegfried. Latest: Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).

3
deals tracked
2
announced in 2026
$148.6m
disclosed value (3 deals)
67%
licensing, the top deal type
  • EPT has tracked 3 Chile pharma deals (2022–2026), 2 of them announced in 2026.
  • The most common structures are licensing (67%) & m&a (33%).
  • Values were disclosed for 3 of 3 deals, totalling $148.6m; the largest is Orchid Pharma → Laboratorio Libra ($80m, 24 Oct 2026).

Countries involved

Argentina (1) · Brazil (1) · China (1) · India (1) · Mexico (1) · Uruguay (1)

Largest disclosed deals

Questions

How many Chile pharma deals has EPT tracked?
3 as of 19 Nov 2026, covering 2022–2026; 2 were announced in 2026. The most recent is Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).
What types of Chile pharma deals are most common?
Licensing: 2 (67%); M&A / Acquisition: 1 (33%).
What is the largest disclosed Chile pharma deal?
Orchid Pharma → Laboratorio Libra: $80m (Licensing, 24 Oct 2026); Shanghai Henlius Biotech → Eurofarma: $50.5m (Licensing, 11 May 2022); Laboratorios Siegfried → Laboratorio Chile: $18.1m (M&A / Acquisition, 19 Nov 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)